Cargando…
Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
Autores principales: | Wängler, Carmen, Beyer, Leonie, Bartenstein, Peter, Wängler, Björn, Schirrmacher, Ralf, Lindner, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445141/ https://www.ncbi.nlm.nih.gov/pubmed/36064987 http://dx.doi.org/10.1186/s41181-022-00176-x |
Ejemplares similares
-
Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021) -
Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023) -
Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023) -
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023) -
Good practices for the automated production of (18)F-SiFA radiopharmaceuticals
por: Blok, Simon, et al.
Publicado: (2023)